Cox John 4
4 · Dyne Therapeutics, Inc. · Filed Dec 5, 2025
Insider Transaction Report
Form 4
Cox John
DirectorCEO & President
Transactions
- Sale
Common Stock
2025-12-05$20.72/sh−2,662$55,157→ 196,877 total
Holdings
- 18,000(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
- [F2]The Reporting Person's sale of shares of Common Stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to the extent of 2,662 shares, with the Reporting Person's purchase of 100,000 shares on July 14, 2025. The Reporting Person has paid to the Issuer an aggregate amount of $31,111.88, representing the amount of the profit deemed realized in connection with the short-swing transaction under Section 16(b) of the Exchange Act.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.58 to $20.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
- [F4]Includes 108,976 unvested RSUs.
- [F5]These shares are held in a trust for the benefit of a child of the Reporting Person.